Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Yingluo
Contact Yingluo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
Highlights • A proteomic and phosphoproteomic landscape of 43 KRAS mutant cancer cell lines • Multi-omic analysis reveals three subsets with distinct characteristics • Compensatory phosphoprotein biomarker analysis identifies new drug combinations • DOT1L and SHP2 inhibition synergistically treats a subset of KRAS mutant cancer Summary KRAS mutant cancer, characterized by the activation of a plethora of phosphorylation signaling pathways, remains a major challenge for cancer therapy.
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Yingluo
Contact Yingluo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack